Novavax, Inc. (NVAX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$10.22-1.16%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NVAX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Raise and deliver Adjusted Total Revenue between $235 million and $275 million for full year 2026, excluding Sanofi-related revenue components.
Stated as a priority in 3 of last 3 quarters. Management raised the 2026 revenue framework from $230-$270 million to $235-$275 million between 2026-Q1 and 2026-Q2. Actual quarterly revenue declined from $140 million in 2026-Q1 to $57 million in 2026-Q2, reflecting seasonality and transition to Sanofi. The trajectory shows management maintaining and slightly raising the revenue target while actual revenue fluctuates, consistent with their stated framework.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Novavax raised its 2026 Revenue Framework and expects Adjusted Total Revenue to between $235 million and $275 million.”
“Novavax reiterates its 2026 Revenue Framework and expects Adjusted Total Revenue of between $230 million and $270 million.”
“Novavax raised its 2026 Revenue Framework and expects Adjusted Total Revenue between $235 million and $275 million.”
Maintain disciplined cost management targeting Non-GAAP combined R&D and SG&A expenses between $310 million and $340 million for full year 2026.
Stated as a priority in 3 of last 3 quarters. Management maintained Non-GAAP combined R&D and SG&A expense guidance at $310-$340 million for 2026, improving GAAP guidance slightly in 2026-Q2. Actual R&D expenses decreased from $95 million in 2026-Q1 to $71 million in 2026-Q2, and SG&A expenses decreased slightly from $29 million to $27 million. The trajectory shows management delivering cost discipline consistent with their guidance.
“Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point while maintaining Non-GAAP Combined R&D and SG&A Expense guidance of $310 - $340 million.”
“Targeting full year Non-GAAP combined R&D and SG&A expenses of $310 - $340 million for full year 2026.”
“Non-GAAP Combined R&D and SG&A Expenses $310 - $340 million for full year 2026.”
Grow Matrix-M technology partnerships and license agreements with pharmaceutical and biotech companies across infectious disease and oncology.
Stated as a priority in 2 of last 3 quarters. Management announced a new Matrix-M license agreement with Pfizer including a $30 million upfront payment in 2026-Q1 and multiple MTAs with top pharmaceutical companies to explore Matrix-M applications. This reflects active partnership expansion consistent with management's stated growth strategy.
“In January 2026, Novavax entered into a license agreement with Pfizer for use of Matrix-M in two infectious disease areas and signed multiple MTAs with pharma companies.”
“Novavax expanded Matrix-M partnering efforts with global pharmaceutical companies and innovative biopharma companies.”
Progress development of Clostridioides difficile vaccine candidate with potential clinical entry as early as 2027.
Stated as a priority in 2 of last 3 quarters. Management reiterated the goal to advance the C. difficile vaccine candidate into clinical trials as early as 2027. While no financial or clinical milestone data is yet available, the repeated statements indicate ongoing focus consistent with the stated timeline.
“On track to advance C. difficile vaccine program into the clinic as early as 2027.”
“C. difficile vaccine candidate prioritized as potential next asset to enter the clinic as early as 2027.”
Finalize transfer of Nuvaxovid manufacturing technology to Sanofi by mid-2027 to trigger milestone payments and expand commercial reach.
Newly stated in 2026-Q2. Management disclosed the expected completion of manufacturing technology transfer to Sanofi by mid-2027, which would trigger a $75 million milestone payment. This is a forward-looking operational milestone with no prior quarterly statements in the supplied data.
“Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a $75 million milestone payment to Novavax.”
Over the trailing year it converted -2.61x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 32% of the time over the next year (vs 54% for the rest of the cohort, n=2490).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
25 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.